An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding - Pat Metharom


image by: Buddy Stephens

HWN Suggests

A new anti-platelet drug shows potential for treating blood vessel clots in heart attacks, strokes and, possibly, COVID-19

Clots obstruct blood vessels and can be deadly. They cause heart attack, stroke and are also a major problem in severe cases of COVID-19 patients. Treating clots with available drugs, however, can cause blood vessel leaking and bleeding, which can also be deadly in some circumstances.

To address this problem, my colleagues and I have engineered a new anti-platelet drug designed to prevent vessel-blocking blood clots without causing bleeding. This drug shows promise in treating heart attack and may also be useful for other severe conditions caused by clots, such as stroke and COVID-19 patients with clots and blood vessel leaks.

As a scientist studying the biology of blood cells…

read full article


 A new anti-platelet drug shows potential for treating blood vessel clots in heart attacks, strokes and, possibly, COVID-19

Anti-platelet drugs have been successfully used to prevent thrombosis, or ‘clotting,’ but they cause blood vessels to leak and bleed, which can make inflammation worse. A new anti-platelet drug address all three conditions.

Antiplatelet Drugs

The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa antagonists. The relationships among dose, efficacy, and safety are discussed along with a mechanistic overview of results of randomized clinical trials. The article does not provide specific management recommendations...

Heart Matters

Antiplatelet medications, such as aspirin and clopidogrel, are commonly used to reduce the risk of heart attack. Senior Cardiac Nurse Christopher Allen finds out more from Professor Albert Ferro.


Antiplatelet drugs work to make your platelets less sticky and thereby help prevent blood clots from forming in your arteries. Aspirin is an antiplatelet drug that may be used. P2Y12 receptor blockers are another group of antiplatelet drugs. This group of drugs includes: clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor.


All antiplatelet drugs can cause bleeding. Avoid in patients who are at a high risk of bleeding or where the consequences of bleeding would be severe - for example, active peptic ulcer disease, uncontrolled hypertension.


Antiplatelet medications divide into oral and parenteral agents. Oral agents subdivide further based on the mechanism of action. Aspirin was the first antiplatelet medication and is a cyclooxygenase inhibitor. Other oral antiplatelet agents include clopidogrel, ticagrelor, prasugrel, pentoxifylline, cilostazol, and dipyridamole. Glycoprotein IIb/IIIa inhibitors such as tirofiban, eptifibatide are only available as parenteral agents and used in acute coronary syndrome.

Introducing Stitches!

Your Path to Meaningful Connections in the World of Health and Medicine
Connect, Collaborate, and Engage!

Coming Soon - Stitches, the innovative chat app from the creators of HWN. Join meaningful conversations on health and medical topics. Share text, images, and videos seamlessly. Connect directly within HWN's topic pages and articles.

Be the first to know when Stitches starts accepting users

Stay Connected